Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised

EMA/PE/0000229973

Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Date of authorisation: 24/07/2024, Revision: 3, Status: Authorised

EMA/PE/0000227014

Abbreviations used in EMA scientific committees and Coordination Group for Mutual Recognition and Decentralised Procedures (CMD) documents, and in relation to EMA’s regulatory activities

EMA/PE/0000230592

EMA/PE/0000242035

Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000234339

EMA/PE/0000237724

Opinion/decision on a Paediatric investigation plan (PIP): Ocrevus, ocrelizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: EMA/PE/0000237224